{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:23:52Z","timestamp":1791829432258,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T00:00:00Z","timestamp":1629072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["314061271"],"award-info":[{"award-number":["314061271"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["641696"],"award-info":[{"award-number":["641696"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["314061271"],"award-info":[{"award-number":["314061271"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["641697"],"award-info":[{"award-number":["641697"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>After radical resection, patients with adrenocortical carcinoma (ACC) frequently experience recurrence and, therefore, effective adjuvant treatment is urgently needed. The aim of the study was to investigate the role of adjuvant platinum-based therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this retrospective multicentre cohort study, we identified patients treated with adjuvant platinum-based chemotherapy after radical resection and compared them with patients without adjuvant chemotherapy. Recurrence-free and overall survival (RFS\/OS) were investigated in a matched group analysis and by applying a propensity score matching using the full control cohort (<jats:italic>n<\/jats:italic>\u2009=\u2009268). For both approaches, we accounted for immortal time bias.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 31 patients in the platinum cohort (R0 <jats:italic>n<\/jats:italic>\u2009=\u200925, RX <jats:italic>n<\/jats:italic>\u2009=\u20094, R1 <jats:italic>n<\/jats:italic>\u2009=\u20092; ENSAT Stage II <jats:italic>n<\/jats:italic>\u2009=\u200911, III <jats:italic>n<\/jats:italic>\u2009=\u200916, IV <jats:italic>n<\/jats:italic>\u2009=\u20094, median Ki67 30%, mitotane <jats:italic>n<\/jats:italic>\u2009=\u200928), 14 experienced recurrence compared to 29 of 31 matched controls (median RFS after the landmark at 3 months 17.3 vs. 7.3 months; adjusted HR 0.19 (95% CI 0.09\u20130.42; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Using propensity score matching, the HR for RFS was 0.45 (0.29\u20130.89, <jats:italic>P<\/jats:italic>\u2009=\u20090.021) and for OS 0.25 (0.09\u20130.69; <jats:italic>P<\/jats:italic>\u2009=\u20090.007).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study provides the first evidence that adjuvant platinum-based chemotherapy may be associated with prolonged recurrence-free and overall survival in patients with ACC and a very high risk for recurrence.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-021-01513-8","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T12:03:47Z","timestamp":1629115427000},"page":"1233-1238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study"],"prefix":"10.1038","volume":"125","author":[{"given":"Otilia","family":"Kimpel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1396-6384","authenticated-orcid":false,"given":"Sara","family":"Bedrose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Megerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Terzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kroiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf M.","family":"Dekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouhammed Amir","family":"Habra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-6398","authenticated-orcid":false,"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,16]]},"reference":[{"key":"1513_CR1","doi-asserted-by":"crossref","unstructured":"Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1476\u201390.","DOI":"10.1016\/j.annonc.2020.08.2099"},{"key":"1513_CR2","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.path.2019.08.010","volume":"12","author":"A Vaidya","year":"2019","unstructured":"Vaidya A, Nehs M, Kilbridge K. Treatment of adrenocortical carcinoma. Surg Pathol Clin. 2019;12:997\u20131006.","journal-title":"Surg Pathol Clin."},{"key":"1513_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ecl.2015.03.001","volume":"44","author":"E Baudin","year":"2015","unstructured":"Baudin E. Endocrine Tumor Board of Gustave R. Adrenocortical carcinoma. Endocrinol Metab Clin North Am. 2015;44:411\u201334.","journal-title":"Endocrinol Metab Clin North Am."},{"key":"1513_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0773-7","volume":"21","author":"S Jasim","year":"2019","unstructured":"Jasim S, Habra MA. Management of adrenocortical carcinoma. Curr Oncol Rep. 2019;21:20.","journal-title":"Curr Oncol Rep."},{"key":"1513_CR5","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35:282\u2013326.","journal-title":"Endocr Rev."},{"key":"1513_CR6","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.eururo.2013.11.006","volume":"65","author":"A Berruti","year":"2014","unstructured":"Berruti A, Fassnacht M, Haak H, Else T, Baudin E, Sperone P, et al. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol. 2014;65:832\u20138.","journal-title":"Eur Urol."},{"key":"1513_CR7","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1056\/NEJMoa063360","volume":"356","author":"M Terzolo","year":"2007","unstructured":"Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372\u201380.","journal-title":"N Engl J Med."},{"key":"1513_CR8","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1210\/jc.2016-2894","volume":"102","author":"A Berruti","year":"2017","unstructured":"Berruti A, Grisanti S, Pulzer A, Claps M, Daffara F, Loli P, et al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. J Clin Endocrinol Metab. 2017;102:1358\u201365.","journal-title":"J Clin Endocrinol Metab."},{"key":"1513_CR9","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179:G1\u2013G46.","journal-title":"Eur J Endocrinol."},{"key":"1513_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/EJE-18-0923","volume":"180","author":"A Calabrese","year":"2019","unstructured":"Calabrese A, Basile V, Puglisi S, Perotti P, Pia A, Saba L, et al. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. Eur J Endocrinol. 2019;180:387\u201396.","journal-title":"Eur J Endocrinol."},{"key":"1513_CR11","doi-asserted-by":"crossref","unstructured":"Puglisi S, Calabrese A, Basile V, Ceccato F, Scaroni C, Altieri B, et al. Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma. Cancers. 2020;12:740.","DOI":"10.3390\/cancers12030740"},{"key":"1513_CR12","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1210\/jc.2008-0579","volume":"93","author":"H Huang","year":"2008","unstructured":"Huang H, Fojo T. Adjuvant mitotane for adrenocortical cancer-a recurring controversy. J Clin Endocrinol Metab. 2008;93:3730\u20132.","journal-title":"J Clin Endocrinol Metab."},{"key":"1513_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.17925\/EE.2018.14.2.62","volume":"14","author":"RM Paragliola","year":"2018","unstructured":"Paragliola RM, Torino F, Papi G, Locantore P, Pontecorvi A, Corsello SM. Role of mitotane in adrenocortical carcinoma\u2014review and state of the art. Eur Endocrinol. 2018;14:62\u20136.","journal-title":"Eur Endocrinol."},{"key":"1513_CR14","doi-asserted-by":"crossref","unstructured":"Puglisi S, Calabrese A, Basile V, Ceccato F, Scaroni C, Simeoli C, et al. Mitotane concentrations influence the risk of recurrence in adrenocortical carcinoma patients on adjuvant treatment. J Clin Med. 2019;8:1850.","DOI":"10.3390\/jcm8111850"},{"key":"1513_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1530\/EJE-13-0242","volume":"169","author":"M Terzolo","year":"2013","unstructured":"Terzolo M, Baudin AE, Ardito A, Kroiss M, Leboulleux S, Daffara F, et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol. 2013;169:263\u201370.","journal-title":"Eur J Endocrinol."},{"key":"1513_CR16","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1210\/jc.2006-1007","volume":"91","author":"M Fassnacht","year":"2006","unstructured":"Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91:4501\u20134.","journal-title":"J Clin Endocrinol Metab."},{"key":"1513_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-020-01533-3","volume":"15","author":"J Zhu","year":"2020","unstructured":"Zhu J, Zheng Z, Shen J, Lian X, Miao Z, Shen J, et al. Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a retrospective study and an updated meta-analysis. Radiat Oncol. 2020;15:118.","journal-title":"Radiat Oncol."},{"key":"1513_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1210\/jc.2012-2367","volume":"98","author":"MA Habra","year":"2013","unstructured":"Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:192\u20137.","journal-title":"J Clin Endocrinol Metab."},{"key":"1513_CR19","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1210\/jc.2019-00029","volume":"104","author":"LA Gharzai","year":"2019","unstructured":"Gharzai LA, Green MD, Griffith KA, Else T, Mayo CS, Hesseltine E, et al. Adjuvant radiation improves recurrence-free survival and overall survival in adrenocortical carcinoma. J Clin Endocrinol Metab. 2019;104:3743\u201350.","journal-title":"J Clin Endocrinol Metab."},{"key":"1513_CR20","doi-asserted-by":"crossref","unstructured":"Bedrose S, Daher M, Altameemi L, Habra MA. Adjuvant therapy in adrenocortical carcinoma: reflections and future directions. Cancers. 2020;12:508.","DOI":"10.3390\/cancers12020508"},{"key":"1513_CR21","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/mpo.10241","volume":"40","author":"L Hovi","year":"2003","unstructured":"Hovi L, Wikstrom S, Vettenranta K, Heikkila P, Saarinen-Pihkala UM. Adrenocortical carcinoma in children: a role for etoposide and cisplatin adjuvant therapy? Preliminary report. Med Pediatr Oncol. 2003;40:324\u20136.","journal-title":"Med Pediatr Oncol."},{"key":"1513_CR22","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1023\/A:1008377915129","volume":"11","author":"TS Khan","year":"2000","unstructured":"Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, et al. Streptozocin and o,p\u2019DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol. 2000;11:1281\u20137.","journal-title":"Ann Oncol."},{"key":"1513_CR23","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189\u201397.","journal-title":"N Engl J Med."},{"key":"1513_CR24","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1210\/jc.2017-01624","volume":"102","author":"JEK Henning","year":"2017","unstructured":"Henning JEK, Deutschbein T, Altieri B, Steinhauer S, Kircher S, Sbiera S, et al. Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors. J Clin Endocrinol Metab. 2017;102:4323\u201332.","journal-title":"J Clin Endocrinol Metab."},{"key":"1513_CR25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16:426\u201335.","journal-title":"Lancet Oncol."},{"key":"1513_CR26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/cncr.24030","volume":"115","author":"M Fassnacht","year":"2009","unstructured":"Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer. 2009;115:243\u201350.","journal-title":"Cancer."},{"key":"1513_CR27","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1038\/onc.2017.54","volume":"36","author":"M Batisse-Lignier","year":"2017","unstructured":"Batisse-Lignier M, Sahut-Barnola I, Tissier F, Dumontet T, Mathieu M, Drelon C, et al. P53\/Rb inhibition induces metastatic adrenocortical carcinomas in a preclinical transgenic model. Oncogene. 2017;36:4445\u201356.","journal-title":"Oncogene."},{"key":"1513_CR28","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1530\/EJE-20-1124","volume":"184","author":"OM Dekkers","year":"2021","unstructured":"Dekkers OM, Groenwold RHH. When observational studies can give wrong answers: the potential of immortal time bias. Eur J Endocrinol. 2021;184:E1\u20134.","journal-title":"Eur J Endocrinol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01513-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01513-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01513-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T10:14:01Z","timestamp":1635243241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01513-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,16]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,10,26]]}},"alternative-id":["1513"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01513-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,16]]},"assertion":[{"value":"20 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This cohort study was part of the ENSAT registry study () in four European reference centres for ACC (W\u00fcrzburg, Germany; Brescia, Italy; Berlin, Germany; and Orbassano, Italy) and the MD Anderson Cancer Center in Houston, US. It was approved by the ethics committees\/institutional review boards at all participating institutions and all patients provided written informed consent. It was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"MK received travel cost reimbursement, speaker honoraria, and research support from Ipsen Pharma. AB received funds for research in adrenocortical carcinoma from Novartis, Janssen Cilag and Sanofi. MT received speaker honoraria and research grants from HRA Pharma that were paid to the University Department. MAH received honoraria from HRA Pharma for the advisory board. MF has served in an advisory board of HRA Pharma on the management of adrenocortical carcinoma (2018 + 2021); remuneration was paid to his University Hospital. OK, SB, FM, KM and OMD declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}